In summary, we have developed LNP delivery technology incorporating GalNAc-based ASGPR-targeting ligands and tested that technology in a NHP model of HoFH characterized by somatic LDLR-deficiency in the liver. This evidence concerns the gene ASGR1 and homozygous familial hypercholesterolemia.